Twinlab Consolidated (TLCC) 10-Q 14 May 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	14-May-15
Document Information [Line Items]
Entity Registrant Name	TWINLAB CONSOLIDATED HOLDINGS, INC.
Entity Central Index Key	1590695
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Trading Symbol	TLCC
Entity Common Stock, Shares Outstanding		220,000,000
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash	$918	$437
Restricted cash	0	370
Marketable securities	57	29
Accounts receivable, net of allowance of $2,449 and $2,372, respectively	8,635	4,604
Inventories, net	16,158	18,418
Prepaid expenses and other current assets	3,829	4,421
Total current assets	29,597	28,279
Property, plant and equipment, net	4,014	2,680
Intangible assets, net	10,919	7,564
Goodwill	8,818	0
Other assets	640	986
Total assets	53,988	39,509
Current liabilities:
Checks written in excess of cash	300	708
Accounts payable	19,533	12,900
Accrued expenses and other current liabilities	4,796	2,061
Derivative liabilities	6,261	0
Notes payable and current portion of long-term debt, net of discount	25,187	13,653
Total current liabilities	56,077	29,322
Long-term liabilities:
Deferred gain on sale of assets	2,011	2,052
Long-term debt, net of current portion and discount	6,657	12,772
Total long-term liabilities	8,668	14,824
Total liabilities	64,745	44,146
Commitments and contingencies
Stockholders’ deficit:
Common stock, $0.001 par value, 5,000,000,000 shares authorized, 220,000,000 shares issued and outstanding	220	220
Additional paid-in capital	182,166	182,704
Stock subscriptions receivable	-100	-100
Accumulated deficit	-192,988	-187,378
Accumulated other comprehensive loss	-55	-83
Total stockholders’ deficit	-10,757	-4,637
Total liabilities and stockholders' deficit	$53,988	$39,509

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, except Share data, unless otherwise specified
Common stock, par value (in dollars per share)	$0.00	$0.00
Common Stock, Shares Authorized	5,000,000,000	5,000,000,000
Common Stock, Shares, Issued	220,000,000	220,000,000
Common Stock, Shares, Outstanding	220,000,000	220,000,000
Allowance for Doubtful Accounts Receivable, Current	$2,449	$2,372

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Net sales	$22,072	$18,669
Cost of sales	18,460	13,885
Gross profit	3,612	4,784
Selling, general and administrative expenses	7,492	6,344
Loss from operations	-3,880	-1,560
Other income (expense):
Interest expense, net	-1,731	-1,345
Other income, net	2	6
Total other expense	-1,729	-1,339
Loss before income taxes	-5,609	-2,899
Provision for income taxes	-1	-3
Net loss	-5,610	-2,902
Other comprehensive loss - unrealized gain (loss) on marketable securities	28	-9
Total comprehensive loss	($5,582)	($2,911)
Weighted average number of common shares outstanding - basic and diluted (in shares)	220,000,000	199,995,000
Loss per common share - basic and diluted (in dollars per share)	($0.03)	($0.01)

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net loss	($5,610)	($2,902)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	235	296
Amortization of debt discount	489	0
Stock-based compensation	292	0
Provision for obsolete inventory	114	74
Provision for losses on accounts receivable	49	-7
Changes in operating assets and liabilities:
Accounts receivable	-4,080	-2,140
Inventories	2,146	119
Prepaid expenses and other current assets	242	-360
Other assets	-37	0
Checks written in excess of cash	-408	172
Accounts payable	6,633	1,992
Accrued expenses and other current liabilities	861	-62
Net cash provided by (used in) operating activities	926	-2,818
Cash flows from investing activities:
Cash paid in acquisition	-6,126	0
Purchases of property, plant and equipment	-1,455	-56
Change in restricted cash	370	-2
Net cash used in investing activities	-7,211	-58
Cash flows from financing activities:
Proceeds from the issuance of debt	8,867	21,725
Repayment of debt	-1,579	-18,727
(Increase) decrease in security deposits	19	-30
Payment of debt issuance costs	-541	0
Net cash provided by financing activities	6,766	2,968
Net increase in cash	481	92
Cash at the beginning of the period	437	300
Cash at the end of the period	918	392
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest	1,165	825
Cash paid for income taxes	12	10
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING TRANSACTIONS:
Change in unrealized holding gain (loss) on marketable securities	28	-9
Accrued interest payable added to debt principal	0	2,263
Consideration exchanged:
Debt issued	3,978	0
Liabilities assumed	1,874	0
Other assets	350	0
Assets acquired:
Intangible assets	3,510	0
Goodwill (net of cash paid of $8,818)	2,692	0
Other assets transferred to debt discount	364	0
Warrant value transferred from additional paid-in capital to debt discount	3,109	0
Issuance of warrants for additional paid-in capital and debt discount	2,279	0
Issuance of warrants for derivative liability and debt discount	$3,152	$0

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Goodwill, Acquired During Period	$8,818

NATURE_OF_OPERATIONS_AND_SUMMA

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE 1 – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Organization
	Twinlab Consolidated Holdings, Inc. (the “Company”) was incorporated on October 24, 2013 under the laws of the State of Nevada as Mirror Me, Inc. On August 7, 2014, the Company amended its articles of incorporation and changed its name to Twinlab Consolidated Holdings, Inc.
	Nature of Operations
	The Company and its subsidiaries manufacture and market high-quality, science-based nutritional supplements, and also provide health and wellness information. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Twinlab Consolidation Corporation (“TCC”), Twinlab Holdings, Inc. (“THI”), Twinlab Corporation (“Twinlab”), ISI Brands, Inc. (“ISI”), NutraScience Labs, Inc. (“NutraScience”) and NutraScience IP Corporation.
	Products include vitamins, minerals, specialty supplements and sports nutrition products primarily under the Twinlab® brand name (including the Twinlab® Fuel family of sports nutrition products); diet and energy products under the Metabolife® brand name; a line of products that promote joint health under the Trigosamine® brand name; and a full line of herbal teas under the Alvita® brand name. These products are sold primarily through health and natural food stores and national and regional drug store chains, supermarkets, and mass market retailers.
	Principles of Consolidation
	The condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.
	Nutricap Purchase Agreement
	As further discussed in Note 3, on February 6, 2015, NutraScience acquired the customer relationships of Nutricap Labs, LLC, a provider of dietary supplement contract manufacturing services.
	Basis of Presentation and Unaudited Information
	The condensed consolidated interim financial statements included herein have been prepared by the Company in accordance with United States generally accepted accounting principles, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management, are necessary for fair presentation of the information contained therein. Financial results for any interim period are not necessarily indicative of financial results that may be expected for the fiscal year. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K filed with the SEC on March 31, 2015.
	Use of Estimates
	The preparation of financial statements in conformity with U.S. generally accepted accounting requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Actual results could differ from those estimates. Significant management estimates include those with respect to returns and allowances, allowance for doubtful accounts, reserve for inventory obsolescence, recoverability of long-lived assets and estimated value of warrants.
	Significant Concentration of Credit Risk
	Sales to the Company’s top three major customers aggregated to approximately 37% and  33% of total sales for the three months ended March 31, 2015 and 2014, respectively. Sales to one of those customers were approximately 26% and 19% of total sales for the three months ended March 31, 2015 and 2014, respectively. Accounts receivable from these customers were approximately  37% and 24% of total accounts receivable as of March 31, 2015 and December 31, 2014, respectively.
	Geographic Concentrations
	Net revenues from customers residing in the following foreign countries were as follows for the three months ended March 31, 2014 and 2013:
		March 31,		% of Total			March 31,		% of Total
		2015		Revenues			2014		Revenues
	Mexico	$	218		0.99	%	$	509		2.73	%
	Canada	$	555		2.52	%	$	704		3.77	%
	Other	$	1,284		5.82	%	$	1,582		8.47	%
	Fair Value of Financial Instruments
	The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:
	Level 1 – inputs are quoted prices in active markets for identical assets that the reporting entity has the ability to access at the measurement date.
	Level 2 – inputs are other than quoted prices included within Level 1 that are observable for the asset, either directly or indirectly.
	Level 3 – inputs are unobservable inputs for the asset that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability.
	The following table summarizes the financial instruments of the Company measured at fair value on a recurring basis as of March 31, 2015 and December 31, 2014:
	March 31, 2015	Total		Level 1			Level 2		Level 3
	Marketable securities	$	57	$	57		$	-	$	-
	Derivative liability		6,261		-			-		6,261
	December 31, 2014	Total		Level 1			Level 2		Level 3
	Marketable securities	$	29	$	29		$	-	$	-
	Net Loss per Common Share
	Basic net income or loss per common share (Basic EPS) is computed by dividing net income or loss by the weighted average number of common shares outstanding. Diluted net income or loss per common share (Diluted EPS) is computed by dividing net income or loss by the sum of the weighted average number of common shares outstanding and the dilutive potential common share equivalents then outstanding. Potential dilutive common share equivalents consist of shares issuable upon the exercise of outstanding stock options and warrants to acquire common stock.
	Due to the fact that for all periods presented, the Company incurred net losses, potential dilutive common share equivalents as of March 31, 2015 and December 31, 2014, totaling 89,871,978 and 84,683,227, respectively, are not included in the calculation of Diluted EPS because they are anti-dilutive. Therefore, basic loss per common share is the same as diluted loss per common share for the three months ended March 31, 2015 and 2014.
	Recent Accounting Pronouncements
	In April 2015, the Financial Accounting Standards Board issued ASU No. 2015-03, “Interest – Imputation of Interest (Subtopic 835-30), Simplifying the Presentation of Debt Issuance Costs.” To simplify presentation of debt issuance costs, the amendments in this Update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this Update. For public companies, the amendments in this Update are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Early adoption of the amendments in this Update is permitted for financial statements that have not been previously issued. We adopted the new guidance effective January 1, 2015. Our prior period financial statements were not impacted by the early adoption of this Update.

GOING_CONCERN

GOING CONCERN	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern Disclosure [Text Block]	NOTE 2 – GOING CONCERN
	The accompanying consolidated financial statements have been prepared on a going concern basis, which assumes continuity of operations and realization of assets and liabilities in the ordinary course of business. Since their formation, the Company and its subsidiaries have operated at a loss. At March 31, 2015, the Company had an accumulated deficit of $192,988 and a total stockholders’ deficit of $10,757. These losses were associated with start-up activities and brand and infrastructure development. Recently, losses were primarily attributable to lower than planned sales resulting from low fill rates on ordered demand due to our working capital deficiency, delayed product introductions and postponed marketing activities, merger-related and other restructuring costs, and interest and refinancing charges associated with the Company’s debt refinancing. Losses have been funded primarily through issuance of common stock, borrowings from the Company’s stockholders and third-party debt.
	Because of this history of operating losses and significant interest expense on the Company’s debt, the Company has a working capital deficiency of $26,480 at March 31, 2015. The Company also has significant debt payments due within the next 12 months and significant debt classified as a current liability due to non-compliance with debt covenants.
	Management continues to address and make significant progress with the operating issues; however, these continuing conditions raise substantial doubt about the Company's ability to continue as a going concern.
	Management has addressed operating issues through the following actions: focusing on growing the core business and brands; continuing emphasis on major customers and key products; and reducing manufacturing and operating costs and continuing to negotiate lower prices from major suppliers. Management believes that it will be able to service its debt obligations in 2015, however, there can be no assurance that the Company will be able to meet its debt obligations as they become due. In connection with the Merger, management was able to convert a majority of the Company’s outstanding debt to equity. Additionally, management believes that by improving operations, continuing to focus on cost reductions and harnessing synergies from the Nutricap asset acquisition, the Company will be able to fund operations over the next twelve months; however, there can be no assurance that the Company will be able to improve operations or reduce costs (see Note 3).
	The Company’s adjusted EBITDA as of March 31, 2015 was not in compliance with the Minimum Adjusted EBITDA covenants in the Senior Credit Facility and two notes payable to institutional investors (see Note 7). Consequently, the full amount of these obligations are included in current liabilities in our condensed consolidated balance sheet as of March 31, 2015.
	The consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

NUTRICAP_ASSET_ACQUISITION

NUTRICAP ASSET ACQUISITION	3 Months Ended
	Mar. 31, 2015
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	NOTE 3 – NUTRICAP ASSET ACQUISITION
	TCC entered into an option agreement in September 2014 (the “Option Agreement”) that gave TCC an exclusive option to purchase certain assets of a provider of dietary supplement contract manufacturing services (“Nutricap”). Pursuant to the Option Agreement, as amended and restated and further amended, and an Asset Purchase Agreement (the “Nutricap Purchase Agreement”), dated and effective as of February 4, 2015, the acquisition was consummated on February 6, 2015 by NutraScience.
	Nutricap provides dietary supplement contract manufacturing services. Pursuant to the Nutricap Purchase Agreement, NutraScience acquired Nutricap’s customer relationships. NutraScience assumed certain of the liabilities of Nutricap, including, without limitation, liabilities for (i) certain taxes; and (ii) NutraScience’s agreement to offer a credit to any customer in an amount equal to the amount of any Customer Deposit (as defined in the Nutricap Purchase Agreement) placed by such customer in connection with an existing purchase order with respect to which such customer agrees to novate such purchase order with NutraScience pursuant to a Novation Contract (as defined in the Nutricap Purchase Agreement).
	The aggregate consideration for the purchased assets is comprised of the following:
	Cash ($8,000 reduced by customer deposits of $1,874)	$	6,126
	Deposit paid in 2014		350
	Novation contract deposit credit liability		1,874
	Short-term notes payable to Nutricap		3,978
	Total purchase price	$	12,328
	The purchase price has been allocated as follows:
	Customer relationships	$	3,510
	Goodwill		8,818
	Total	$	12,328
	The customer relationships are amortized over an estimated economic life of ten years using the straight-line method.
	The short-term notes payable to Nutricap include a promissory note of $2,500 bearing interest at a rate of 6% per annum and maturing 60 days after the closing of the acquisition, which note currently remains unpaid, and a promissory note of $1,478 bearing interest at a rate of 3% per annum, payable in 12 equal monthly installments of principal and interest commencing in February 2015. The failure to pay the $2,500 note at maturity resulted in a $250 late payment penalty.
	The parties entered into a Transition Services Agreement, dated February 6, 2015, pursuant to which Nutricap will provide NutraScience with certain transitional services to assist in the transfer of the customer relationships acquired pursuant to the Nutricap Purchase Agreement (the “TSA”). The TSA provides that Nutricap will provide NutraScience with, among other services, (i) the services of certain Nutricap personnel; (ii) the right to use Nutricap’s premises; (iii) access to Nutricap’s information services; and (iv) accounting services.
	The TSA is in effect until August 6, 2015 subject to NutraScience’s right to extend the term of the TSA for up to an additional 6 months. Notwithstanding the foregoing, NutraScience has the right to discontinue provision of services under the TSA prior to the end of the term but will still be responsible for paying the costs of using Nutricap’s premises through the end of the term.
	NutraScience will pay Nutricap the following fees pursuant to the TSA: (i) a monthly fee of $300; (ii) $259 in 12 equal monthly installments for use of Nutricap’s premises; (iii) applicable retention bonuses for certain individuals employed by Nutricap who perform transition services under the TSA; and (iv) 105% of any actual shipping and warehousing expenses incurred by Nutricap at the request and on behalf of NutraScience.

INVENTORIES

INVENTORIES	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	NOTE 4 – INVENTORIES
	Inventories consisted of the following at:
		March 31,		December 31,
		2015		2014
	Raw materials	$	5,813	$	8,757
	Work in process		2,229		2,492
	Finished goods		9,799		8,738
			17,841		19,987
	Reserve for obsolete inventory		-1,683		-1,569
		$	16,158	$	18,418

PROPERTY_AND_EQUIPMENT

PROPERTY AND EQUIPMENT	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	NOTE 5 – PROPERTY AND EQUIPMENT
	Property and equipment consisted of the following at:
		March 31,		December 31,
		2015		2014
	Machinery and equipment	$	10,762	$	10,366
	Computers and other		7,650		6,593
	Land		577		577
	Aquifer		482		482
	Leasehold improvements		1,515		1,515
			20,986		19,533
	Accumulated depreciation and amortization		-16,972		-16,853
		$	4,014	$	2,680
	Assets held under capital leases are included in machinery and equipment and amounted to $572 and $2,169 as of March 31, 2015 and December 31, 2014, respectively.
	Depreciation and amortization expense totaled $121 and $202 for the three months ended March 31, 2015 and 2014, respectively.

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure [Text Block]	NOTE 6 – INTANGIBLE ASSETS
	Intangible assets consisted of the following at:
		March 31,		December 31,
		2015		2014
	Trademarks	$	10,142	$	10,142
	Customer relationships		5,334		1,824
			15,476		11,966
	Accumulated amortization		-4,557		-4,402
		$	10,919	$	7,564
	Trademarks are amortized over a period of 30 years and customer relationships are amortized over periods ranging from 10 to 16 years. Amortization expense was $155 and $117 for the three months ended March 31, 2015 and 2014, respectively.

DEBT

DEBT	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	NOTE 7 – DEBT
	Debt consisted of the following at:
		March 31,			December 31,
		2015			2014
	Related-Party Debt: Note payable to an entity owned by stockholders, unsecured, with an imputed interest rate of 16.2%, maturing through July 25, 2017	$	8,958		$	9,797
	Senior Credit Facility: Revolving $15,000 asset-based credit facility payable to an institutional lender, with an interest rate equal to LIBOR plus 5% and expiring on January 22, 2018, net of discount of $486		10,326			-
	Notes Payable: Notes payable to an institutional lender, with interest rate of 12%, maturing in November 2019, net of discount of $6,417		3,583			4,994
	Note Payable: Note payable to an institutional lender, with interest rate of 12%, maturing in February 2020, net of discount of $1,950		3,050			-
	Vendor Term Notes: Unsecured loans payable to vendors with rates ranging from 7% to 6% and maturity dates of November 2014 and May 2015		96			520
	Note Payable: Unsecured note payable issued pursuant to the Nutricap Purchase Agreement, bearing interest at a rate of 3% per annum, payable in 12 equal monthly installments of principal and interest commencing in February 2015 (see description in Note 3 above)		1,356			-
	Note Payable: Unsecured note payable issued pursuant to the Nutricap Purchase Agreement, bearing interest at a rate of 6% per annum and maturing 60 days after the closing of the Nutricap acquisition (see description in Note 3 above)		2,500			-
	Capital Lease Obligations: Capital leases with rates ranging from 10.5% to 10.25% and maturity dates ranging from October 2016 to July 2017, secured by certain manufacturing equipment in the American Fork facility		1,975			2,169
	Senior Credit Facility: Revolving $9,500 asset-based credit facility payable to a financial institution, repaid in 2015		-			8,945
	Total		31,844			26,425
	Less current portion		(25,187	)		(13,653	)
	Long-term debt	$	6,657		$	12,772
	Certain of the debt agreements require the Company to meet certain affirmative and negative covenants, including maintenance of specified ratios. The Company’s Adjusted EBITDA as of March 31, 2015 was not in compliance with the Minimum Adjusted EBITDA covenants in the Senior Credit Facility, the note payable to an institutional investor for $3,583, and the note payable to an institutional investor for $3,050. Consequently, the full amount of these obligations are included in current liabilities in our condensed consolidated balance sheet as of March 31, 2015.
	Pursuant to a July 2014 “Debt Repayment Agreement” with a related party, the Company is obligated pay such party $4,900 per year in structured monthly payments for 3 years provided that such payment obligations will terminate at such earlier time as the trailing ninety day volume weighted average closing sales price of the Company on all domestic securities exchanges on which it is listed equals or exceeds $5.06 per share.
	On November 13, 2014, the Company raised proceeds of $8,000, less certain fees and expenses, from the issuance of a note to an institutional investor. The note matures on November 13, 2019 with payments of principal due on a quarterly basis commencing November 13, 2017 in installments starting at $360 per quarter and increasing to $520 per quarter. Interest at an original rate of 12% is payable monthly commencing on November 30, 2014. The Company (i) granted the investor a security interest in the Company’s assets and (ii) pledged the shares of its subsidiaries as security for the note. The investor also agreed to purchase from the Company an additional note in the amount of $2,000, no later than November 13, 2015. The Company issued warrants in connection with this loan (see Note 8 below).
	On February 6, 2015, the Company raised proceeds of $2,000, less certain fees and expenses, from the institutional investor who purchased the $8,000 note discussed in the preceding paragraph. The proceeds were restricted to pay a portion of the Nutricap acquisition discussed in Note 3. This note matures on November 13, 2019 with payments of principal due on a quarterly basis commencing November 13, 2017 in installments starting at $90 per quarter and increasing to $130 per quarter. Interest at an original rate of 12% is payable monthly commencing on February 28, 2015. The Company issued warrants in connection with this loan (see Note 8 below).
	On January 22, 2015, the Company paid off all amounts owed under its credit facility with Fifth Third Bank and entered into a new three-year $15,000 revolving credit facility based on the Company’s accounts receivable and inventory, increasable to up to $20,000, with MidCap Financial Trust, which assigned the agreement to an affiliate, Midcap Funding X Trust (“MidCap”), on January 23, 2015. The Company (i) granted MidCap a first priority security interest in certain of its assets and (ii) pledged the shares of its subsidiaries as security for amounts owed under the credit facility. The Company is required to pay Midcap an unused line fee of 0.042% per month and a collateral management fee of 0.10% per month. The Company issued warrants in connection with this loan (see Note 8 below).
	On January 22, 2015, the Company raised proceeds of $5,000 less certain fees and expenses, from the sale of a note to an institutional investor. The proceeds were restricted to pay a portion of the Nutricap asset acquisition discussed in Note 3. The note matures on February 13, 2020 with payments of principal due on a quarterly basis commencing March 1, 2017 in installments starting at $250 per quarter and increasing to $350 per quarter. Interest is payable monthly commencing on February 2, 2015. The Company (i) granted the investor a security interest in the Company’s assets, including real estate and (ii) pledged the shares of its subsidiaries as security for the note. The Company issued warrants in connection with this loan (see Note 8 below).

WARRANTS_COMMON_STOCK_PUT_AGRE

WARRANTS, COMMON STOCK PUT AGREEMENT AND REGISTRATION RIGHTS AGREEMENTS	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	NOTE 8 – WARRANTS, COMMON STOCK PUT AGREEMENT AND REGISTRATION RIGHTS AGREEMENTS
	In connection with a September 3, 2014 related party debt agreement, TCC issued to the lender a warrant to acquire 5,592,105 shares of TCC common stock at a purchase price of $0.76 per share at any time prior to September 6, 2017. The warrant agreement contains certain anti-dilution provisions, and through March 31, 2015, the number of common shares that may be acquired was increased by 185,306 shares .
	The Company issued a Series A Warrant (the “Series A Warrant”) to Capstone Financial Group, Inc. (“Capstone”), effective as of September 30, 2014. Pursuant to the Series A Warrant, Capstone has the right to purchase up to 52,631,579 shares of common stock at an exercise price of $0.76 per share. The Series A Warrant is exercisable from October 1, 2014 through October 31, 2017. The Series A Warrant provides for equitable adjustments in the event of a stock split, stock dividend, reclassification, consolidation or merger. The Company has agreed with Capstone that if the Company issues a security (i) exercisable or exchangeable for or (ii) convertible into shares of common stock at a date after October 1, 2014 and such security provides for anti-dilution protection, the shares of common stock issuable under the Series A Warrant shall enjoy the same anti-dilution protection as that first issued security.
	The Company also issued a Series B Warrant (the “Series B Warrant”) to Capstone, effective as of September 30, 2014. Pursuant to the Series B Warrant, Capstone has the right to purchase up to 22,368,421 shares of common stock at an exercise price of $0.76 per share. The Series B Warrant is exercisable from October 1, 2014 through October 31, 2017 but only to the extent and in the same proportions as exercises by Capstone of the Series A Warrant. The Series B Warrant provides for equitable adjustments in the event of a stock split, stock dividend, reclassification, consolidation or merger. The Company has agreed with Capstone that if the Company issues a security (i) exercisable or exchangeable for or (ii) convertible into shares of common stock at a date after October 1, 2014 and such security provides for anti-dilution protection, the shares of common stock issuable under the Series B Warrant shall enjoy the same anti-dilution protection as that first issued security.
	The Company and Capstone have entered into a Common Stock Put Agreement, dated as of September 30, 2014, as amended on December 15, 2014 (as so amended, the “Put Agreement”), pursuant to which Capstone indicated its intent to exercise the Series A Warrant over a 36 month term at a monthly rate of no less than 1,461,988 shares of common stock commencing on November 15, 2014 and on a monthly basis thereafter. In the event that Capstone does not exercise the Series A Warrant such that as of February 16, 2015 or any applicable exercise date thereafter, Capstone’s cumulative purchases of common stock pursuant to the Series A Warrant has not been at a rate that is equal to or in excess of the minimum rate, then the Company has the right to notify Capstone of the Company’s exercise of its put rights under the Put Agreement. Upon receipt of such notice, Capstone is required to exercise the Series A Warrant to (i) purchase by a date identified in the notice, such amount of common stock as would, if purchased as of February 16, 2015 or any applicable exercise date, have made Capstone’s purchases of common stock pursuant to the Series A Warrant as of such exercise date equal to the minimum rate, and (ii) purchase by a date that is no later than each subsequent periodic exercise date an amount of common stock such that as of each such periodic exercise date, Capstone’s cumulative purchases of common stock pursuant to the Series A Warrant through that date will have been at a rate that is no less than the minimum rate. Following delivery of the put notice by the Company, Capstone’s failure to make the initial mandatory purchase by the put date is an “Event of Default”. Following the delivery of the put notice by the Company, Capstone’s failure to make when due any periodic mandatory purchase is a breach of the Put Agreement, and if such breach is not timely cured by Capstone, such uncured breach will be deemed an Event of Default. Upon the occurrence of an Event of Default as described above, (i) Capstone’s right to purchase all shares of common stock remaining unpurchased under the Series A Warrant is converted into an obligation, accelerated and immediately due and (ii) the Series B Warrant immediately terminates as to any shares of common stock remaining exercisable under the Series B Warrant. In the event the Company invokes its right pursuant to the put notice to require Capstone to exercise the Series A Warrant, the exercise price per share of common stock thereunder is $0.775 per share. In the event that the Company converts and accelerates Capstone’s obligations to purchase the shares of common stock remaining unexercised under the Series A Warrant, Capstone has the right to surrender issued and outstanding shares of common stock to the Company to be credited towards Capstone’s obligations, with such surrendered shares valued at $0.76 per share of common stock. As of March 31, 2015, the Company had not received funds related to the Series A Warrant and the Company had not delivered the put notice.
	The Company and Capstone entered into a Registration Rights Agreement, dated as of September 30, 2014 (the “Registration Agreement”). Pursuant to the Registration Agreement, Capstone can require the Company to register the shares of common stock acquired upon exercise of the Series A Warrant and the Series B Warrant at such time as the Company is eligible to register securities on a Registration Statement on Form S-3 and thereafter file additional registration statements if requested by Capstone on a quarterly basis. The Registration Agreement contains terms and conditions customary for the grant of registration rights.
	In connection with the November 13, 2014 note for $8,000, the institutional investor was issued a warrant to acquire 4,091,122 shares of common stock at an aggregate purchase price of $0.01 through November 13, 2019. Subsequently, and in connection with the additional $2,000 note from the same institutional investor, the warrant was cancelled and replaced on February 6, 2015 by a warrant to purchase a total of 4,960,740 shares of common stock at an aggregate exercise price of $0.01. The other terms of this warrant are the same as the warrant issued on November 13, 2014. In connection with this institutional investor’s consent to the terms of additional debt obtained by the Company on January 22, 2015, the Company granted this institutional investor a warrant to acquire a total of 869,618 shares of common stock at a purchase price of $1.00 per share, through November 13, 2019. Both warrant agreements grant the investor certain registration rights, commencing October 1, 2015, for the shares of common stock issuable on exercise of the warrants.
	The institutional investor has the right, under certain circumstances, to require the Company to purchase all or any portion of the equity interest in the Company issued or represented by the warrant to acquire 4,960,740 shares at a price based on the greater of (i) the product of (x) ten times the Company’s adjusted EBITDA with respect to the twelve months preceding the exercise of the put right times (y) the investor’s percentage ownership in the Company assuming full exercise of the warrant; or (ii) the fair market value of the investor’s equity interest underlying the warrant. In the event (i) the Company does not have the funds available to repurchase the equity interest under the warrant or (ii) such repurchase is not lawful, adjustments to the principal of the note purchased by such investor will be made or, under certain circumstances, interest will be charged on the amount otherwise due for such repurchase.
	The Company has the right, under certain circumstances, to require the investor to sell to the Company all or any portion of the equity interest issued or represented by the warrant to acquire 4,960,740 shares. The price for such repurchase will be the greater of (i) the product of (x) eleven times the Company’s adjusted EBITDA with respect to the twelve months preceding the exercise of the call right times (y) the investor’s percentage ownership in the Company assuming full exercise of the warrant; or (ii) the fair market value of the equity interests underlying the warrant; or (iii) $3,750.
	In connection with the line of credit agreement with MidCap described in Note 7, the Company issued MidCap a warrant, exercisable through January 22, 2018, for an aggregate of 500,000 shares of the Company’s common stock at an exercise price of $0.76 per share (the “MidCap Warrant”). The Company and MidCap have entered into a Registration Rights Agreement, dated as of January 22, 2015, granting MidCap certain registration rights, commencing October 1, 2015, for the shares of common stock issuable on exercise of the MidCap Warrant.
	In connection with the January 22, 2015 note payable to an institutional investor, the Company issued the investor warrants to purchase an aggregate of 2,329,400 shares of common stock, at an aggregate exercise price of $0.01, through February 13, 2020. On February 4, 2015, the Company also granted to the investor a warrant to acquire a total of 434,809 shares of common stock at a purchase price of $1.00 per share, through February 13, 2020. Both warrant agreements grant the investor certain registration rights, commencing October 1, 2015, for the shares of common stock issuable upon exercise of the warrants.
	The shares issuable pursuant to the warrants granted during the three months ended March 31, 2015 are generally subject to adjustment on terms and conditions customary for transactions of this nature in the event of (i) reorganization, recapitalization, stock split-up, combination of shares, mergers, consolidations and (ii) sale of all or substantially all of the Company’s assets or property. In addition, the Company is required to give additional anti-dilution protection under the MidCap Warrant in the event the Company issues a security exercisable for or convertible into shares of Common Stock and such security contains anti-dilution protection. The number of shares of common stock issuable pursuant to the January 22, 2015 warrants for 2,329,400 shares and the February 6, 2015 warrants for 4,960,740 shares will be increased if the Company’s audited adjusted EBITDA for the fiscal year ending December 31, 2018 is less than $19,250.
	A summary of the status of the warrants issued by the Company as of March 31, 2015, and changes during the three months then ended is presented below:
				Weighted
				Average
		Shares		Exercise Price
	Outstanding, December 31, 2014		84,683,227	$	0.72
	Granted		9,279,873	$	0.2
	Canceled / Expired		-4,091,122	$	0
	Exercised		-	$	-
	Outstanding, March 31, 2015		89,871,978	$	0.68

DERIVATIVE_LIABILITIES

DERIVATIVE LIABILITIES	3 Months Ended
	Mar. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Fair Value [Text Block]	NOTE 9 – DERIVATIVE LIABILITIES
	The number of shares of common stock issuable pursuant to the January 22, 2015 warrants for 2,329,400 shares and the February 6, 2015 warrants for 4,960,740 shares will be increased if the Company’s audited adjusted EBITDA for the fiscal year ending December 31, 2018 is less than $19,250.
	The Company has recorded these warrants as derivative liabilities due to the variable terms of the warrant agreements and accordingly, has estimated the total fair value of the derivative liabilities at $6,261 as of March 31, 2015.
	During the three months ended March 31, 2015, the Company had the following activity in its derivative liabilities account:
	Derivative liabilities at December 31, 2014	$	-
	Addition to liabilities for new warrants issued		6,261
	Derivative liabilities at March 31, 2015	$	6,261

STOCKHOLDERS_DEFICIT

STOCKHOLDERS' DEFICIT	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 10 – STOCKHOLDERS’ DEFICIT
	The Company has authorized preferred stock of 500,000,000 shares. No shares of the preferred stock have been issued.
	The only equity compensation plan currently in effect is the Twinlab Consolidation Corporation 2013 Stock Incentive Plan (the “TCC Plan”), which was assumed by the Company on September 16, 2014. The TCC Plan originally established a pool of 20,000,000 shares of common stock for issuance as incentive awards to employees for the purposes of attracting and retaining qualified employees who will aid in the success of the Company. From January through March 2015, the Company granted to certain employees of the Company a total of 7,503,252 Restricted Stock Units pursuant to the TCC Plan. Each Restricted Stock Unit relates to one share of the Company’s common stock. The Restricted Stock Unit awards vest 25% each on January 1, 2016, January 1, 2017, January 1, 2018 and January 1, 2019. The Company estimated the grant date value of the Restricted Stock Units at $0.76 per share, and will amortize the total estimated grant date value over the vesting periods.

OPTION_AGREEMENT

OPTION AGREEMENT	3 Months Ended
	Mar. 31, 2015
Business Combinations [Abstract]
Business Combination, Option Agreements Disclosure [Text Block]	NOTE 11 – OPTION AGREEMENT
	In September 2014, TCC entered into an option agreement ("Option No. 1") that gives TCC an exclusive option to purchase 100% of the equity of a marketer and distributor of nutritional products (“Target No. 1”) on certain agreed upon terms.  TCC paid $2,000 to acquire Option No. 1, which is included in prepaid expenses and other current assets in the accompanying consolidated balance sheets as of March 31, 2015 and December 31, 2014.  Option No. 1 can be exercised on or before July 13, 2015.  As an option, the Company will have the right, but not the obligation, to acquire the equity of Target No. 1 for a purchase price of $37,000, payable in cash at the closing of the acquisition without reduction for the option purchase price.  At present none of the Company, TCC or any other subsidiary of the Company has sufficient funds necessary to close on the acquisition of the equity of Target No. 1, if it were to exercise Option No. 1.  The Company believes that it and TCC will be able to raise the necessary funds to exercise Option No. 1 on a timely basis, although there can be no assurance that the Company and TCC will be successful.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 12 – SUBSEQUENT EVENTS
	Warrant Exercises
	On April 6, 2015, Capstone exercised its right to purchase an aggregate of 263,158 shares of common stock pursuant to the Series A Warrant dated September 30, 2014 (see Note 8). Proceeds to the Company were $200.
	On April 20, 2015, Capstone exercised its right to purchase an aggregate of 394,737 shares of Common Stock pursuant to the Series A Warrant dated September 30, 2014. Proceeds to the Company were $300.
	Tolworthy Surrender Agreement
	As previously disclosed, on September 3, 2014, TCC entered into a Subscription and Surrender Agreement with Thomas Tolworthy, which agreement was assumed by the Company on September 16, 2014 in connection with the merger with TCC (the “Surrender Agreement”). Pursuant to the Surrender Agreement, Mr. Tolworthy is required, upon request by the Company, to surrender up to 65,306,102 shares of common stock for use by the Company. On May 11, 2015, the Company requested pursuant to the Surrender Agreement, and Mr. Tolworthy agreed, to surrender 697,895 shares to the Company, which shares will be placed in the treasury.
	Office Lease Agreement
	On April 7, 2015, the Company and TCC, as co-tenants, entered into an Office Lease Agreement (the “Lease”) for premises in the St. Petersburg, Florida (“Building”). The term of the Lease is for twelve years, commencing on May 1, 2015 and ending on April 30, 2027. The Company has options to extend the term of the Lease for two additional periods of five years each and certain rights of first offer and rights of first refusal to lease additional space at the Building. Upon delivery of the leased premises by the landlord, the Company will establish a new corporate headquarters in St. Petersburg, which shall be the Company’s principal offices.
	The Company is initially leasing the fifth floor of the Building (the “Initial Premises”). Pursuant to the terms of the Lease, the Company is required to expand the Initial Premises to include the sixth floor of the Building (the “First Expansion Premises”) between February 1, 2016 and October 31, 2016, upon notice to the landlord and provided that the landlord is not obligated to deliver the First Expansion Premises unless the Company then has a traded market capitalization of $50 million or more for the immediately preceding thirty days prior to the date of the Company’s exercise notice (the “Market Cap Test”).
	The aggregate amount of Annual Base Rent to be paid over the term of the Lease is $4,466 for the Initial Premises (plus a proportionate share of annual Operating Expenses and Taxes as set forth in the Lease). In the event that the Company leases the First Expansion Premises, Annual Base Rent for the First Expansion Premises will be paid at the same rental rate payable for the Initial Premises and, if leased by the Company at the earliest date available under the Lease, will result in additional payments of up to approximately $4,552 (plus a proportionate share of annual Operating Expenses and Taxes as set forth in the Lease) over the term of the Lease.
	The Lease requires the Company to deposit a $1,000 security deposit with the landlord, which is payable in the form of cash or a letter of credit no later than July 1, 2015. If on May 1, 2018 (or on any subsequent May 1st during the term of the Lease), the Company satisfies the Market Cap Test, the landlord is required to return the entire security deposit to the Company.
	JL Properties Reimbursement Agreement
	On April 30, 2015, JL Properties, Inc., an Alaska corporation (“JLP”), the Company and TCC entered into a Reimbursement Agreement (the “JLP Agreement”), pursuant to which, and in order to satisfy the Company’s obligation to provide a $1,000 security deposit in connection with Lease as referenced above, JLP agreed to arrange for and provide, on or before May 1, 2015, an unconditional, irrevocable, transferable, and negotiable commercial letter of credit in the amount of $1,000, which letter of credit will automatically renew on an annual basis for a five (5) year term expiring on April 30, 2020 (the “LOC”).
	In the event the LOC is drawn upon (each, a “Draw Amount”), the Company and TCC are jointly obligated to reimburse JLP, commencing on the sixth (6th ) month anniversary of the date that the LOC is drawn upon, in semi-annual installments of fifty percent (50%) of the Draw Amount, plus interest. A final payment of the entire Draw Amount and accrued interest will be due and payable on the first anniversary of the date that the LOC is drawn upon. Interest will be charged at the greater of (i) federal interest rate for mid-term obligations published by the Internal Revenue Service as of the date the LOC is drawn upon or (ii) the federal interest rate that JLP is required to pay to the issuer of the LOC in connection with the draw on the LOC. A Draw Amount may be prepaid, in whole or in part, at any time without premium or penalty.
	In the event that all or any portion of an installment of a Draw Amount is not paid within fifteen (15) days after notice of such failure from JLP (each an, "Unpaid Installment"), JLP will have the option to require that the Company issue to JLP (i) a warrant, in substantially the form of the First JLP Warrant (as defined below), in the aggregate amount of "XX" shares of common stock exercisable at a purchase price of $0.01 in the aggregate and (ii) a warrant, in substantially the form of the Second Warrant (as defined below), in the aggregate amount of "YY" shares of common stock exercisable at a purchase price of $1.00 per share; provided, however, that the Company has no obligation to issue such additional warrants so long as the failure to pay an installment of the Draw Amount arises out of a prohibition to pay, and JLP’s preclusion to accept, a payment of the Draw Amount under the terms of any of those certain subordination agreements separately entered into as of April 30, 2015, by and between JLP on the one hand, and each of the Company’s lenders, MidCap, Penta Mezzanine SBIC Fund I, L.P. (“Penta”), and JL-BBNC Mezz Utah, LLC (“JL - BBNC”), on the other hand. For purposes of the warrants to be issued as described above (i) "XX" shall mean the applicable unpaid Draw Amount divided by $1,000, multiplied by 465,880 and further multiplied by two and (ii) "YY" shall mean the applicable unpaid Draw Amount divided by $1,000, multiplied by 86,962 and further multiplied by two. Warrants issued as described above will be in full satisfaction of the obligation to pay the unpaid Draw Amounts for which such warrants are issued.
	JLP is an affiliate of (i) JL - BBNC, a lender to the Company, and (ii) Utah Lab, LLC, from whom Twinlab leases its Utah manufacturing facility. The relationship between the Company and JL - BBNC was previously disclosed in the Company’s Current Reports on Form 8-K, filed with the SEC on January 28, 2015 and February 9, 2015, which Reports are hereby incorporated by reference herein.
	As partial consideration for the entry by JLP into the JLP Agreement and the provision of the LOC, the Company issued JLP two warrants to purchase shares of common stock.
	The first warrant (the “First JLP Warrant”) is exercisable for an aggregate of 465,880 shares of common stock, subject to certain adjustments, at an aggregate purchase price of $0.01, at any time prior to April 30, 2020. In addition to adjustments on terms and conditions customary for a transaction of this nature in the event of (i) reorganization, recapitalization, stock split-up, combination of shares, mergers, consolidations and (ii) sale of all or substantially all of the Company’s assets or property, the number of shares of common stock issuable pursuant to the First JLP Warrant will be increased in the event the Company’s and its Subsidiaries’ (as defined in the First JLP Warrant) audited Adjusted EBITDA (as defined in the First JLP Warrant) for the fiscal year ending December 31, 2018 does not equal or exceed $19,250.
	The second warrant (the “Second JLP Warrant”) is exercisable for an aggregate of 86,962 shares of common stock, at a per share purchase price of $1.00, at any time prior to April 30, 2020. The number of shares issuable upon exercise of the Second JLP Warrant is subject to adjustment on terms and conditions customary for a transaction of this nature in the event of (i) reorganization, recapitalization, stock split-up, combination of shares, mergers, consolidations and (ii) sale of all or substantially all of the Company’s assets or property.
	The Company has granted JLP certain registration rights, commencing October 1, 2015, for the shares of common stock issuable on exercise of the First and Second JLP Warrants.

NATURE_OF_OPERATIONS_AND_SUMMA1

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Organization [Policy Text Block]	Organization
	Twinlab Consolidated Holdings, Inc. (the “Company”) was incorporated on October 24, 2013 under the laws of the State of Nevada as Mirror Me, Inc. On August 7, 2014, the Company amended its articles of incorporation and changed its name to Twinlab Consolidated Holdings, Inc.
Nature Of Operations [Policy Text Block]	Nature of Operations
	The Company and its subsidiaries manufacture and market high-quality, science-based nutritional supplements, and also provide health and wellness information. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Twinlab Consolidation Corporation (“TCC”), Twinlab Holdings, Inc. (“THI”), Twinlab Corporation (“Twinlab”), ISI Brands, Inc. (“ISI”), NutraScience Labs, Inc. (“NutraScience”) and NutraScience IP Corporation.
	Products include vitamins, minerals, specialty supplements and sports nutrition products primarily under the Twinlab® brand name (including the Twinlab® Fuel family of sports nutrition products); diet and energy products under the Metabolife® brand name; a line of products that promote joint health under the Trigosamine® brand name; and a full line of herbal teas under the Alvita® brand name. These products are sold primarily through health and natural food stores and national and regional drug store chains, supermarkets, and mass market retailers.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation
	The condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.
Nutricap Purchase Agreement [Policy Text Block]	Nutricap Purchase Agreement
	As further discussed in Note 3, on February 6, 2015, NutraScience acquired the customer relationships of Nutricap Labs, LLC, a provider of dietary supplement contract manufacturing services.
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation and Unaudited Information
	The condensed consolidated interim financial statements included herein have been prepared by the Company in accordance with United States generally accepted accounting principles, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management, are necessary for fair presentation of the information contained therein. Financial results for any interim period are not necessarily indicative of financial results that may be expected for the fiscal year. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K filed with the SEC on March 31, 2015.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates
	The preparation of financial statements in conformity with U.S. generally accepted accounting requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Actual results could differ from those estimates. Significant management estimates include those with respect to returns and allowances, allowance for doubtful accounts, reserve for inventory obsolescence, recoverability of long-lived assets and estimated value of warrants.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Significant Concentration of Credit Risk
	Sales to the Company’s top three major customers aggregated to approximately 37% and  33% of total sales for the three months ended March 31, 2015 and 2014, respectively. Sales to one of those customers were approximately 26% and 19% of total sales for the three months ended March 31, 2015 and 2014, respectively. Accounts receivable from these customers were approximately  37% and 24% of total accounts receivable as of March 31, 2015 and December 31, 2014, respectively.
Segment Reporting, Policy [Policy Text Block]	Geographic Concentrations
	Net revenues from customers residing in the following foreign countries were as follows for the three months ended March 31, 2014 and 2013:
		March 31,		% of Total			March 31,		% of Total
		2015		Revenues			2014		Revenues
	Mexico	$	218		0.99	%	$	509		2.73	%
	Canada	$	555		2.52	%	$	704		3.77	%
	Other	$	1,284		5.82	%	$	1,582		8.47	%
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments
	The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:
	Level 1 – inputs are quoted prices in active markets for identical assets that the reporting entity has the ability to access at the measurement date.
	Level 2 – inputs are other than quoted prices included within Level 1 that are observable for the asset, either directly or indirectly.
	Level 3 – inputs are unobservable inputs for the asset that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability.
	The following table summarizes the financial instruments of the Company measured at fair value on a recurring basis as of March 31, 2015 and December 31, 2014:
	March 31, 2015	Total		Level 1			Level 2		Level 3
	Marketable securities	$	57	$	57		$	-	$	-
	Derivative liability		6,261		-			-		6,261
	December 31, 2014	Total		Level 1			Level 2		Level 3
	Marketable securities	$	29	$	29		$	-	$	-
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Common Share
	Basic net income or loss per common share (Basic EPS) is computed by dividing net income or loss by the weighted average number of common shares outstanding. Diluted net income or loss per common share (Diluted EPS) is computed by dividing net income or loss by the sum of the weighted average number of common shares outstanding and the dilutive potential common share equivalents then outstanding. Potential dilutive common share equivalents consist of shares issuable upon the exercise of outstanding stock options and warrants to acquire common stock.
	Due to the fact that for all periods presented, the Company incurred net losses, potential dilutive common share equivalents as of March 31, 2015 and December 31, 2014, totaling 89,871,978 and 84,683,227, respectively, are not included in the calculation of Diluted EPS because they are anti-dilutive. Therefore, basic loss per common share is the same as diluted loss per common share for the three months ended March 31, 2015 and 2014.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements
	In April 2015, the Financial Accounting Standards Board issued ASU No. 2015-03, “Interest – Imputation of Interest (Subtopic 835-30), Simplifying the Presentation of Debt Issuance Costs.” To simplify presentation of debt issuance costs, the amendments in this Update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this Update. For public companies, the amendments in this Update are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Early adoption of the amendments in this Update is permitted for financial statements that have not been previously issued. We adopted the new guidance effective January 1, 2015. Our prior period financial statements were not impacted by the early adoption of this Update.

NATURE_OF_OPERATIONS_AND_SUMMA2

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Net revenues from customers residing in the following foreign countries were as follows for the three months ended March 31, 2014 and 2013:
		March 31,		% of Total			March 31,		% of Total
		2015		Revenues			2014		Revenues
	Mexico	$	218		0.99	%	$	509		2.73	%
	Canada	$	555		2.52	%	$	704		3.77	%
	Other	$	1,284		5.82	%	$	1,582		8.47	%
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	The following table summarizes the financial instruments of the Company measured at fair value on a recurring basis as of March 31, 2015 and December 31, 2014:
	March 31, 2015	Total		Level 1			Level 2		Level 3
	Marketable securities	$	57	$	57		$	-	$	-
	Derivative liability		6,261		-			-		6,261
	December 31, 2014	Total		Level 1			Level 2		Level 3
	Marketable securities	$	29	$	29		$	-	$	-

NUTRICAP_ASSET_ACQUISITION_Tab

NUTRICAP ASSET ACQUISITION (Tables)	3 Months Ended
	Mar. 31, 2015
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	The aggregate consideration for the purchased assets is comprised of the following:
	Cash ($8,000 reduced by customer deposits of $1,874)	$	6,126
	Deposit paid in 2014		350
	Novation contract deposit credit liability		1,874
	Short-term notes payable to Nutricap		3,978
	Total purchase price	$	12,328
Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]	The purchase price has been allocated as follows:
	Customer relationships	$	3,510
	Goodwill		8,818
	Total	$	12,328

INVENTORIES_Tables

INVENTORIES (Tables)	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventories consisted of the following at:
		March 31,		December 31,
		2015		2014
	Raw materials	$	5,813	$	8,757
	Work in process		2,229		2,492
	Finished goods		9,799		8,738
			17,841		19,987
	Reserve for obsolete inventory		-1,683		-1,569
		$	16,158	$	18,418

PROPERTY_AND_EQUIPMENT_Tables

PROPERTY AND EQUIPMENT (Tables)	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment consisted of the following at:
		March 31,		December 31,
		2015		2014
	Machinery and equipment	$	10,762	$	10,366
	Computers and other		7,650		6,593
	Land		577		577
	Aquifer		482		482
	Leasehold improvements		1,515		1,515
			20,986		19,533
	Accumulated depreciation and amortization		-16,972		-16,853
		$	4,014	$	2,680

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Intangible assets consisted of the following at:
		March 31,		December 31,
		2015		2014
	Trademarks	$	10,142	$	10,142
	Customer relationships		5,334		1,824
			15,476		11,966
	Accumulated amortization		-4,557		-4,402
		$	10,919	$	7,564

DEBT_Tables

DEBT (Tables)	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	Debt consisted of the following at:
		March 31,			December 31,
		2015			2014
	Related-Party Debt: Note payable to an entity owned by stockholders, unsecured, with an imputed interest rate of 16.2%, maturing through July 25, 2017	$	8,958		$	9,797
	Senior Credit Facility: Revolving $15,000 asset-based credit facility payable to an institutional lender, with an interest rate equal to LIBOR plus 5% and expiring on January 22, 2018, net of discount of $486		10,326			-
	Notes Payable: Notes payable to an institutional lender, with interest rate of 12%, maturing in November 2019, net of discount of $6,417		3,583			4,994
	Note Payable: Note payable to an institutional lender, with interest rate of 12%, maturing in February 2020, net of discount of $1,950		3,050			-
	Vendor Term Notes: Unsecured loans payable to vendors with rates ranging from 7% to 6% and maturity dates of November 2014 and May 2015		96			520
	Note Payable: Unsecured note payable issued pursuant to the Nutricap Purchase Agreement, bearing interest at a rate of 3% per annum, payable in 12 equal monthly installments of principal and interest commencing in February 2015 (see description in Note 3 above)		1,356			-
	Note Payable: Unsecured note payable issued pursuant to the Nutricap Purchase Agreement, bearing interest at a rate of 6% per annum and maturing 60 days after the closing of the Nutricap acquisition (see description in Note 3 above)		2,500			-
	Capital Lease Obligations: Capital leases with rates ranging from 10.5% to 10.25% and maturity dates ranging from October 2016 to July 2017, secured by certain manufacturing equipment in the American Fork facility		1,975			2,169
	Senior Credit Facility: Revolving $9,500 asset-based credit facility payable to a financial institution, repaid in 2015		-			8,945
	Total		31,844			26,425
	Less current portion		(25,187	)		(13,653	)
	Long-term debt	$	6,657		$	12,772

WARRANTS_COMMON_STOCK_PUT_AGRE1

WARRANTS, COMMON STOCK PUT AGREEMENT AND REGISTRATION RIGHTS AGREEMENTS (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	A summary of the status of the warrants issued by the Company as of March 31, 2015, and changes during the three months then ended is presented below:
				Weighted
				Average
		Shares		Exercise Price
	Outstanding, December 31, 2014		84,683,227	$	0.72
	Granted		9,279,873	$	0.2
	Canceled / Expired		-4,091,122	$	0
	Exercised		-	$	-
	Outstanding, March 31, 2015		89,871,978	$	0.68

DERIVATIVE_LIABILITIES_Tables

DERIVATIVE LIABILITIES (Tables)	3 Months Ended
	Mar. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	During the three months ended March 31, 2015, the Company had the following activity in its derivative liabilities account:
	Derivative liabilities at December 31, 2014	$	-
	Addition to liabilities for new warrants issued		6,261
	Derivative liabilities at March 31, 2015	$	6,261

NATURE_OF_OPERATIONS_AND_SUMMA3

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (Sales Revenue, Net [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Mexico [Member]
Segment Reporting Information [Line Items]
Revenue	$218	$509
Concentration Risk, Percentage	0.99%	2.73%
Canada [Member]
Segment Reporting Information [Line Items]
Revenue	555	704
Concentration Risk, Percentage	2.52%	3.77%
Other [Member]
Segment Reporting Information [Line Items]
Revenue	$1,284	$1,582
Concentration Risk, Percentage	5.82%	8.47%

NATURE_OF_OPERATIONS_AND_SUMMA4

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability	$6,261	$0
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability	6,261
Fair Value, Measurements, Recurring [Member] | Marketable Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	57	29
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Marketable Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	57	29
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Marketable Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	0	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability	6,261
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Marketable Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	$0	$0

NATURE_OF_OPERATIONS_AND_SUMMA5

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual)	3 Months Ended	12 Months Ended	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014
Concentration Risk [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	89,871,978	84,683,227
Sales Revenue, Net [Member] | Three Customers [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	37.00%		33.00%
Sales Revenue, Net [Member] | Customer One [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	26.00%		19.00%
Accounts Receivable [Member] | Three Customers [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	37.00%	24.00%

GOING_CONCERN_Details_Textual

GOING CONCERN (Details Textual) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Going Concern [Line Items]
Retained Earnings (Accumulated Deficit)	($192,988)	($187,378)
Stockholders' Equity Attributable to Parent	-10,757	-4,637
Working Capital Deficiency	$26,480

NUTRICAP_ASSET_ACQUISITION_Det

NUTRICAP ASSET ACQUISITION (Details) (Nutricap [Member], USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Business Combination, Contingent Consideration, Asset	$12,328
Cash In Business Combination [Member]
Business Combination, Contingent Consideration, Asset	6,126
Deposit Paid [Member]
Business Combination, Contingent Consideration, Asset	350
Novation Contract Deposit Credit Liability [Member]
Business Combination, Contingent Consideration, Asset	1,874
Short Term Notes Payable To Nutricap [Member]
Business Combination, Contingent Consideration, Asset	$3,978

NUTRICAP_ASSET_ACQUISITION_Det1

NUTRICAP ASSET ACQUISITION (Details) (Parenthetical) (Nutricap [Member], USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Business Combination, Contingent Consideration, Asset	$12,328
Cash Including Customer Deposits [Member]
Business Combination, Contingent Consideration, Asset	8,000
Customer Deposits [Member]
Business Combination, Contingent Consideration, Asset	$1,874

NUTRICAP_ASSET_ACQUISITION_Det2

NUTRICAP ASSET ACQUISITION (Details 1) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Goodwill	$8,818	$0
Nutricap [Member]
Customer relationships	3,510
Goodwill	8,818
Total	$12,328

NUTRICAP_ASSET_ACQUISITION_Det3

NUTRICAP ASSET ACQUISITION (Details Textual) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Feb. 04, 2015
Penalty payable	$250
Transition Services Agreement [Member] | Scenario, Forecast [Member]
Transition Services Fee	300
Business Combination, Integration Related Costs	259
Percentage Of Expenses	105.00%
Nutricap [Member] | Promissory Note Payable In 60 Days [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt		2,500
Debt Instrument, Interest Rate, Stated Percentage		6.00%
Nutricap [Member] | Promissory Note Payable In 12 Equal Monthly Installments [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt		$1,478
Debt Instrument, Interest Rate, Stated Percentage		3.00%

INVENTORIES_Details

INVENTORIES (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Inventory [Line Items]
Raw materials	$5,813	$8,757
Work in process	2,229	2,492
Finished goods	9,799	8,738
Inventory, Gross	17,841	19,987
Reserve for obsolete inventory	-1,683	-1,569
Inventory, Net	$16,158	$18,418

PROPERTY_AND_EQUIPMENT_Details

PROPERTY AND EQUIPMENT (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$20,986	$19,533
Accumulated depreciation and amortization	-16,972	-16,853
Property, Plant and Equipment, Net	4,014	2,680
Machinery and equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Net	10,762	10,366
Computers and other [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Net	7,650	6,593
Land [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Net	577	577
Aquifer [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Net	482	482
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Net	$1,515	$1,515

PROPERTY_AND_EQUIPMENT_Details1

PROPERTY AND EQUIPMENT (Details Textual) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Depreciation	$121	$202
Equipment [Member]
Property, Plant and Equipment [Line Items]
Capital Leased Assets, Gross			2,169
Machinery [Member]
Property, Plant and Equipment [Line Items]
Capital Leased Assets, Gross	$572

INTANGIBLE_ASSETS_Details

INTANGIBLE ASSETS (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$15,476	$11,966
Accumulated amortization	-4,557	-4,402
Finite-Lived Intangible Assets, Net	10,919	7,564
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	10,142	10,142
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$5,334	$1,824

INTANGIBLE_ASSETS_Details_Text

INTANGIBLE ASSETS (Details Textual) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$155	$117
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	30 years
Customer Relationships [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	16 years
Customer Relationships [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	10 years

DEBT_Details

DEBT (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Debt Instrument [Line Items]
Capital Lease Obligations: Capital leases with rates ranging from 10.5% to 10.25% and maturity dates ranging from October 2016 to July 2017, secured by certain manufacturing equipment in the American Fork facility	$1,975	$2,169
Total	31,844	26,425
Less current portion	-25,187	-13,653
Long-term debt	6,657	12,772
Notes Payable maturing in November 2019 [Member]
Debt Instrument [Line Items]
Note Payable	3,583	4,994
Note Payable maturing in February 2020 [Member]
Debt Instrument [Line Items]
Note Payable	3,050	0
Unsecured note payable maturity February 2015 [Member]
Debt Instrument [Line Items]
Note Payable	1,356	0
Unsecured note payable maturing 60 days after [Member]
Debt Instrument [Line Items]
Note Payable	2,500	0
Revolving Credit Facility 15,000 asset-based [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross	10,326	0
Revolving Credit Facility 9,500 asset-based [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross	0	8,945
Related-Party Debt [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross	8,958	9,797
Vendor Term Notes [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross	$96	$520

DEBT_Details_Textual

DEBT (Details Textual) (USD $)	1 Months Ended	3 Months Ended	0 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jan. 22, 2015	Mar. 31, 2015	Feb. 06, 2015	Nov. 13, 2014	Sep. 30, 2014
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment		$4,900
Percentage Of Unused Line Fee Per Month	0.04%
Percentage Of Management Fee Per Month	0.10%
Share Price		$5.06			$0.76
Debt Instrument, Frequency of Periodic Payment		monthly payments for 3 years
Institutional Investor One [Member]
Debt Instrument [Line Items]
Senior Notes, Current		3,583
Institutional Investor Two [Member]
Debt Instrument [Line Items]
Senior Notes, Current		3,050
Subsequent Event [Member] | Fifth Third Bank [Member]
Debt Instrument [Line Items]
Revolving Credit Facility, Maximum Borrowing Capacity	15,000
Increasable Accounts Receivable And Inventory	20,000
Subsequent Event [Member] | Institutional Investor1 [Member]
Debt Instrument [Line Items]
Debt Instrument, Maturity Date	13-Feb-20
Proceeds from Sale of Notes Receivable	5,000
Subsequent Event [Member] | Investor [Member]
Debt Instrument [Line Items]
Debt Instrument, Maturity Date			13-Nov-19
Proceeds from Sale of Notes Receivable			2,000
Debt Instrument, Face Amount			8,000
Scenario, Forecast [Member] | Institutional Investor1 [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment	250
Increased Debt Instrument Periodic Payment	350
Scenario, Forecast [Member] | Investor [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment			90
Increased Debt Instrument Periodic Payment			130
Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		12.00%
Debt Instrument, Maturity Date				13-Nov-19
Proceeds from Sale of Notes Receivable				8,000
Debt Instrument, Face Amount				2,000
Notes Payable, Other Payables [Member] | Scenario, Forecast [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment				360
Increased Debt Instrument Periodic Payment				520
Notes Payable maturing in November 2019 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		12.00%
Debt Instrument, Unamortized Discount		6,417
Note Payable maturing in February 2020 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		12.00%
Debt Instrument, Unamortized Discount		1,950
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		15,000
Debt Instrument, Maturity Date		22-Jan-18
Debt Instrument, Description of Variable Rate Basis		LIBOR plus 5%
Revolving Credit Facility 15,000 asset-based [Member]
Debt Instrument [Line Items]
Debt Instrument, Unamortized Discount		486
Revolving Credit Facility 9,500 asset-based [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		$9,500
Unsecured Related Party Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Maturity Date		25-Jul-17
Debt Instrument, Basis Spread on Variable Rate		16.20%
Capital Lease Obligations [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		10.50%
Debt Instrument Maturity Date Period		Jul-17
Capital Lease Obligations [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		10.25%
Debt Instrument Maturity Date Period		Oct-16
Vendor Term Notes [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		7.00%
Debt Instrument Maturity Date Period		May-15
Vendor Term Notes [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		6.00%
Debt Instrument Maturity Date Period		Nov-14

WARRANTS_COMMON_STOCK_PUT_AGRE2

WARRANTS, COMMON STOCK PUT AGREEMENT AND REGISTRATION RIGHTS AGREEMENTS (Details) (Warrant [Member], USD $)	3 Months Ended
	Mar. 31, 2015
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, December 31, 2014	84,683,227
Granted	9,279,873
Canceled / Expired	-4,091,122
Exercised	0
Outstanding, March 31, 2015	89,871,978
Options, Outstanding, Weighted Average Exercise Price	$0.72
Grants in Period, Weighted Average Exercise Price	$0.20
Canceled / Expired, Weighted Average Exercise Price	$0
Exercised, Weighted Average Exercise Price	$0
Outstanding, Weighted Average Exercise Price	$0.68

WARRANTS_COMMON_STOCK_PUT_AGRE3

WARRANTS, COMMON STOCK PUT AGREEMENT AND REGISTRATION RIGHTS AGREEMENTS (Details Textual) (USD $)	3 Months Ended	0 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Nov. 13, 2014	Sep. 30, 2014	Feb. 06, 2015	Jan. 22, 2015	Sep. 03, 2014	Feb. 04, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Sale of Stock, Price Per Share			$0.78
Share Price	$5.06		$0.76
Proceeds from Notes Payable	$2,000
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding	pursuant to the January 22, 2015 warrants for 2,329,400 shares and the February 6, 2015 warrants for 4,960,740 shares will be increased if the Companys audited adjusted EBITDA for the fiscal year ending December 31, 2018 is less than $19,250.
Class of Warrant or Right, Number of Securities Called by Warrants or Rights Increased	185,306
Institutional Investor [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	4,960,740
Notes Payable, Other Payables [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$0.01	$1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				4,960,740	869,618
Proceeds from Notes Payable		$8,000
Lender [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$0.76
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						5,592,105
Investor [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$0.01
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		4,091,122
Put Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock Issuance Features	The institutional investor has the right, under certain circumstances, to require the Company to purchase all or any portion of the equity interest in the Company issued or represented by the warrant to acquire 4,091,122 shares at a price based on the greater of (i) the product of (x) ten times the Company’s adjusted EBITDA with respect to the twelve months preceding the exercise of the put right times (y) the investor’s percentage ownership in the Company assuming full exercise of the warrant; or (ii) the fair market value of the investor’s equity interest underlying the warrant. In the event (i) the Company does not have the funds available to repurchase the equity interest under the warrant or (ii) such repurchase is not lawful, adjustments to the principal of the note purchased by such investor will be made or, under certain circumstances, interest will be charged on the amount otherwise due for such repurchase.
Call Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock Issuance Features	The Company has the right, under certain circumstances, to require the investor to sell to the Company all or any portion of the equity interest issued or represented by the warrant to acquire 4,091,122 shares. The price for such repurchase will be the greater of (i) the product of (x) eleven times the Company’s adjusted EBITDA with respect to the twelve months preceding the exercise of the call right times (y) the investor’s percentage ownership in the Company assuming full exercise of the warrant; or (ii) the fair market value of the equity interests underlying the warrant; or (iii) $3,750.
Warrant [Member] | MidCap Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$0.76
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					500,000
Warrant [Member] | Institutional Investor [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$0.01		$1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					2,329,400		434,809
Series A Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$0.76
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			52,631,579
Series A Warrant [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			1,461,988
Series B Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$0.76
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			22,368,421

DERIVATIVE_LIABILITIES_Details

DERIVATIVE LIABILITIES (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Derivative Liability	$0
Addition to liabilities for new warrants issued	6,261
Derivative Liability	$6,261

DERIVATIVE_LIABILITIES_Details1

DERIVATIVE LIABILITIES (Details Textual) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding	pursuant to the January 22, 2015 warrants for 2,329,400 shares and the February 6, 2015 warrants for 4,960,740 shares will be increased if the Companys audited adjusted EBITDA for the fiscal year ending December 31, 2018 is less than $19,250.
Derivative Liability	$6,261	$0

STOCKHOLDERS_DEFICIT_Details_T

STOCKHOLDERS' DEFICIT (Details Textual) (USD $)	1 Months Ended				3 Months Ended
	Jan. 31, 2019	Jan. 31, 2018	Jan. 31, 2017	Jan. 31, 2016	Mar. 31, 2015
Preferred Stock, Shares Authorized					500,000,000
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					7,503,252
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	25.00%	25.00%	25.00%	25.00%
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value					$0.76
Employee Stock Option [Member]
Common Stock, Capital Shares Reserved for Future Issuance					20,000,000

OPTION_AGREEMENT_Details_Textu

OPTION AGREEMENT (Details Textual) (Option No.1 [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Option No.1 [Member]
Business Acquisition [Line Items]
Equity Method Investment, Ownership Percentage	100.00%
Payments to Acquire Businesses, Gross	$2,000
Business Combination, Contingent Consideration, payable	$37,000

SUBSEQUENT_EVENTS_Details_Text

SUBSEQUENT EVENTS (Details Textual) (USD $)	0 Months Ended	1 Months Ended			0 Months Ended
	Apr. 07, 2015	Apr. 20, 2015	Apr. 30, 2015	Apr. 06, 2015	11-May-15	Sep. 16, 2014	Nov. 13, 2014
Subsequent Event [Line Items]
Deposits Assets	$1,000,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		394,737		263,158
Description of Warrants Issued			For purposes of the warrants to be issued as described above (i) "XX" shall mean the applicable unpaid Draw Amount divided by $1,000, multiplied by 465,880 and further multiplied by two and (ii) "YY" shall mean the applicable unpaid Draw Amount divided by $1,000, multiplied by 86,962 and further multiplied by two.
Proceeds from Warrant Exercises		300,000		200,000
Traded Market Capitalization	50,000,000
Operating Leases, Rent Expense	4,466,000
Letters of Credit Outstanding, Amount			1,000,000
Common Stock Exercisable Purchase Price Per Share			$1
Subsequent Event [Member] | Surrender Agreement [Member]
Subsequent Event [Line Items]
Stock Repurchased and Retired During Period, Shares					697,895
Subsequent Event [Member] | First Warrant [Member]
Subsequent Event [Line Items]
Warrants Adjustments On Terms And Conditions			In addition to adjustments on terms and conditions customary for a transaction of this nature in the event of (i) reorganization, recapitalization, stock split-up, combination of shares, mergers, consolidations and (ii) sale of all or substantially all of the Companys assets or property, the number of shares of common stock issuable pursuant to the First JLP Warrant will be increased in the event the Companys and its Subsidiaries (as defined in the First JLP Warrant) audited Adjusted EBITDA (as defined in the First JLP Warrant) for the fiscal year ending December 31, 2018 does not equal or exceed $19,250
Warrants Exercisable			465,880
Warrants Exercisable Purchase Price Per Share			$0.01
Subsequent Event [Member] | Second Warrant [Member]
Subsequent Event [Line Items]
Warrants Exercisable			86,962
Warrants Exercisable Purchase Price Per Share			$1
Maximum [Member] | Surrender Agreement [Member]
Subsequent Event [Line Items]
Stock Repurchased and Retired During Period, Shares						65,306,102
Maximum [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Operating Leases, Rent Expense	$4,552,000
Investor [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							4,091,122